Search
pemetrexed (Alimta, LY231514, Rolazar, Tifolar)
Tradename: Alimta (FDA-approved in 2004)
Indications:
1) mesothelioma
2) advanced non-small cell lung cancer [2]
- induction therapy in combination with cisplatin
- maintenance therapy unless component of induction therapy [NGC, NICE]*
- not for maintenance therapy of lung squamous carcinoma [2]
* NICE withdraws guideline 'Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer.' Dec 2016
Mechanism of action:
- folate antagonist
Notes: Manufacturer: Lily
General
folate antagonist; folic acid analog; folic acid antagonist
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 12(2): 2005
New Drugs Approved by the FDA in 2004
Detail-Document#: 210216
(subscription needed) http://www.prescribersletter.com
- Lim MY
Non-Small Cell Lung Cancer: 5 Management Challenges.
Medscape. Nov 30, 2016
http://reference.medscape.com/features/slideshow/non-small-cell-lung-cancer